Under the terms of the agreement, VGX will provide multiple batches of a Cystic fibrosis transmembrane conductance regulator (CFTR) product to support clinical studies planned to run through
This Phase I study is in support of the development of NVC-422 as a product candidate to treat or prevent catheter associated urinary tract infections. In this trial,
Ranbaxy and Merck will work together to develop clinically validated antibacterial and anti-fungal drug candidates. Ranbaxy will carry-out drug discovery and clinical development through Phase IIa clinical trials,
The approval was based on positive results from a Phase III study comparing topotecan hard capsules plus best supportive care (BSC ) to BSC alone in patients with
All patients enrolled in the Sonic II Registry are scheduled for follow-up at 30 days, six months, and one year following the OmniWave procedure. The first patient was
The primary objective of this open-label, single-arm trial is to determine if preoperative administration of NOV-002 in combination with eight cycles of chemotherapy (four of doxorubicin and cyclophosphamide
AGS-004 is a product of the company’s Arcelis technology, a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The target
Forest will record a one-time charge of $44.1 million which is composed of a one-time payment to Daiichi Sankyo of $26.6 million related to the termination and $17.5
The Chinese patent broadly covers all methods of using any RNA interference (‘RNAi’) construct formulated in a supramolecular complex to attenuate the expression of any target gene. Supramolecular
Orphan drug designation for SB1518 will entitle SBIO to tax credits on clinical research after designation and seven years of marketing exclusivity. Other potential benefits include regulatory fee
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.